McKesson Corporation (MCK)
| Market Cap | 101.19B |
| Revenue (ttm) | 387.09B |
| Net Income (ttm) | 4.03B |
| Shares Out | 123.43M |
| EPS (ttm) | 32.12 |
| PE Ratio | 25.47 |
| Forward PE | 19.88 |
| Dividend | $3.28 (0.40%) |
| Ex-Dividend Date | Dec 1, 2025 |
| Volume | 43,971 |
| Open | 818.00 |
| Previous Close | 820.29 |
| Day's Range | 810.48 - 820.00 |
| 52-Week Range | 565.75 - 895.58 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 882.69 (+7.67%) |
| Earnings Date | Feb 4, 2026 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialt... [Read more]
Financial Performance
In 2024, McKesson's revenue was $359.05 billion, an increase of 16.22% compared to the previous year's $308.95 billion. Earnings were $3.30 billion, an increase of 9.76%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MCK stock is "Strong Buy." The 12-month stock price target is $882.69, which is an increase of 7.67% from the latest price.
News
McKesson Corporation: FY26 Earnings Visibility Underpins Buy Case
McKesson Corporation is undervalued despite strong revenue growth, margin expansion, and capital returns; I rate it Buy with a $920 target (13.5% upside). MCK's strategy focuses on boosting margins by...
Mckesson Corporation Announces Third Quarter Fiscal 2026 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a...
Our Top 10 High-Growth Dividend Stocks - December 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
McKesson Corporation (MCK) Presents at Evercore 8th Annual Healthcare Conference Transcript
McKesson Corporation (MCK) Presents at Evercore 8th Annual Healthcare Conference Transcript
McKesson's Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care
IRVING, Texas--(BUSINESS WIRE)--McKesson published its first-ever Advancing Community Oncology Report, a look at the trends influencing community oncology practices across the U.S.
Final Trades: Freeport-McMoRan, Cisco, Teradyne and McKesson Corp.
The Investment Committee give you their top stocks to watch for the second half.
Our Top 10 High Growth Dividend Stocks - November 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
McKesson Corporation (MCK) Presents at UBS Global Healthcare Conference 2025 Transcript
McKesson Corporation ( MCK) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Britt Vitalone - Executive VP & CFO Conference Call Participants Kevin Caliendo - ...
McKesson Corporation (MCK) Q2 2026 Earnings Call Transcript
McKesson Corporation ( MCK) Q2 2026 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jeni Dominguez - Head of Investor Relations Brian Tyler - CEO & Director Britt Vitalone - Executive...
McKesson raises annual profit forecast on robust demand for specialty drugs
Drug distributor McKesson raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology and specialty drug distribution businesses.
McKesson Corporation Reports Fiscal 2026 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on J...
Nike and 3 More Companies Raising the Alarm About Tariff Costs
Plenty of companies will likely boost prices to protect their margins.
The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.
Those looking to buy stocks right now should look for the ones that aren't correlated to the artificial intelligence trade.
McKesson Corporation Transforming Towards High-Margin Operations: Why I Choose To Buy
McKesson Corporation is transforming from a traditional distributor to a tech-enabled healthcare services leader, focusing on high-margin specialty and digital solutions. Recent acquisitions (PRISM Vi...
McKesson: Strategic Shift To High-Growth Oncology And Prescription Tech Signals Long Opportunity
McKesson Corporation is rated 'Buy' due to its transformation into a higher-growth, higher-margin healthcare services platform focused on Oncology & Multispecialty and Prescription Technology Solution...
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
See How McKesson Shares Rise with Money Flows
McKesson Corporation (MCK) shares up 138.5% since Big Money bought big in May 2022.
McKesson Corporation (MCK) Analyst/Investor Day Transcript
McKesson Corporation (NYSE:MCK) Analyst/Investor Day September 23, 2025 9:30 AM EDT Company Participants Brian Tyler - CEO & Director Britt Vitalone - Executive VP & CFO Kirk Kaminsky - President of ...
McKesson lifts annual profit forecast on plans to focus on high-margin businesses
McKesson on Tuesday raised its profit forecast, as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth.
McKesson Corporation Highlights Strategic Growth Strategies and Unveils Updated Long-term Financial Targets at Investor Day
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will host its 2025 Investor Day today, beginning at 9:30 AM ET. During the event, executive leadership will discuss the company's multi...
Drug distributor McKesson to restructure segments to focus on high-margin businesses
McKesson said on Thursday it will restructure its operations into four main segments from the current quarter as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medici...
McKesson Announces New Organizational Structure
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. T...
McKesson Corporation (MCK) Q1 2026 Earnings Call Transcript
McKesson Corporation (NYSE:MCK) Q1 2026 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Brian S. Tyler - CEO & Director Britt J.
Mckesson lifts annual profit forecast on robust demand for specialty drugs
U.S. drug distributor McKesson raised its annual profit forecast and beat Wall Street earnings estimates on Wednesday, banking on robust demand for specialty medicines.